Abstract
It is well known that atherosclerotic vascular disease (ASVD) in the elderly is a global disease with high morbidity, mortality and disability, and plasma LDL-C correction is the most important strategy for ASVD control. However, a large proportion of patients failed to achieve their ideal LDL-C goals after statins use. Ezetimibe, a newly non-statin lipid-lowering agent, is an inhibitor of exogenous cholesterol absorption. Whereby, ezetimibe plus statins may reduce LDL-C more strongly than statins alone. Differed from any other papers published previously, which only involved ezetimibe plus statins for coronary heart disease, the highlight of this paper is to summarize the efficacy and safety of ezetimibe plus statins in all kinds of ASVD subtypes and their related diseases, mainly included aortic atherosclerosis, coronary artery disease, cerebrovascular and peripheral artery diseases. Obviously, this paper is inimitable, which will provide the readers an important reference, especially in treating the elderly with multi-organs atherosclerosis.
Highlights
Atherosclerotic vascular disease (ASVD) is very common in the elderly, included the subtypes of aortic atherosclerosis (AA), cerebrovascular disease (CVD), coronary heart disease (CHD) and peripheral artery disease (PAD), with high morbidity, mortality and disability worldwide [1]
Patients with established CHD and CHD equivalents were considered as in highrisk category (10-year CHD risk >20%), with two or more major risk factors were in moderate-risk category (10-year CHD risk 10% to 20%), and with one or fewer major risk factor were in low-risk category (10-year CHD risk
The co-administration of ezetimibe with rosuvastatin 5 mg provided greater LDLC lowering compared to rosuvastatin 20 mg (−51.6% vs. −49.2%), suggesting that ezetimibe plus a low-dose statin in patients with hypercholesterolemia can produce a comparable or greater reduction in LDL-C compared to a high-dose statin alone, which was consistent with the results from other randomized controlled trials [34,35,36,37,38]
Summary
Atherosclerotic vascular disease (ASVD) is very common in the elderly, included the subtypes of aortic atherosclerosis (AA), cerebrovascular disease (CVD), coronary heart disease (CHD) and peripheral artery disease (PAD), with high morbidity, mortality and disability worldwide [1]. Much evidence revealed that ezetimibe combined with statins could be more effectively to make plasma LDL-C. levels to the goal than statins alone with both routine and high doses (Table 2) [23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]. The co-administration of ezetimibe with rosuvastatin 5 mg provided greater LDLC lowering compared to rosuvastatin 20 mg (−51.6% vs −49.2%), suggesting that ezetimibe plus a low-dose statin in patients with hypercholesterolemia can produce a comparable or greater reduction in LDL-C compared to a high-dose statin alone, which was consistent with the results from other randomized controlled trials [34,35,36,37,38]. Zieve and colleagues found that ezetimibe plus atorvastatin 10 mg more significantly decreased LDL-C at 6 and 12 weeks than doubling or quadrupling dose of atorvastatin alone in elder than 65-year patients with high risk for CHD [27]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
